By Christine A. Wu, Senior Research Analyst, LSN
We are pleased to announce our forty finalists to compete in the Innovation Challenge at LSN’s 2017 RESI in Boston on September 26th. From a pool of over 100 applicants, the LSN Scientific Review Committee has selected a mixture of healthcare IT, diagnostic, therapeutic, and medical device companies, a portion of which have received funding from NIH or partnered with Techstars-Cedars Sinai. The quality of these companies should not go unnoticed, as we have seen nearly 50% of Innovation Challenge finalists from previous RESI events receive funding within one year of their debut.
From a CAR-T therapy for solid tumors to a patient management telehealth platform for chronic diseases, these companies cover a diverse range of life science technologies. Coming from all over the world, the companies will be competing based on scientific merit and investment potential, pitching to RESI attendees and showcasing their innovations. Be sure to meet them and make your “investments” at the RESI Exhibition Hall on September 26th!
Diagnostic
 |
 |
 |
 |
 |
 |
 |
 |
Therapeutic
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Medical Device
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Healthcare IT
 |
 |
 |
Leave a Reply